Olanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study
|
|
- Berniece Rice
- 6 years ago
- Views:
Transcription
1 Originl Article Olnzpine for the prophylxis nd rescue of chemotherpyinduced nuse nd vomiting (CINV): retrospective study Leonrd Chiu, Nichols Chiu, Ronld Chow, Liying Zhng, Mrk Psetk, Jordn Stinson, Brenne Lechner, Ntlie Pulenzs, Sunil Verm, Edwrd Chow, Crlo DeAngelis Sunnybrook Odette Cncer Centre, University of Toronto, Toronto, ON, Cnd Contributions: (I) Conception nd design: L Chiu, E Chow, C DeAngelis; (II) Administrtive support: L Chiu, N Chiu; (III) Provision of study mterils or ptients: C DeAngelis, E Chow; (IV) Collection nd ssembly of dt: L Chiu, L Zhng; (V) Dt nlysis nd interprettion: L Chiu, L Zhng; (VI) Mnuscript writing: All uthors; (VII) Finl pprovl of mnuscript: All uthors. Correspondence to: Dr. Edwrd Chow, MBBS, MSc, PhD, FRCPC. Deprtment of Rdition Oncology, Odette Cncer Centre, Sunnybrook Helth Sciences Centre, 2075 Byview Avenue Toronto, Ontrio M4N 3M5, Cnd. Emil: edwrd.chow@sunnybrook.c. Bckground: While the efficcy of olnzpine in the prophylxis of chemotherpy-induced nuse nd vomiting (CINV) hs been documented, the literture on the use of olnzpine s rescue mediction for brekthrough CINV hs been scrce. The following study retrospectively evluted the sfety nd efficcy of olnzpine for the tretment of brekthrough CINV. The efficcy nd sfety of olnzpine in the prophylctic setting ws lso exmined in smller cohort. Methods: Electronic medicl records of dult ptients ged >17 yers receiving prescription for olnzpine from the Odette Cncer Centre Phrmcy t Sunnybrook Hospitl between Jnury 2013 nd June 2015 were reviewed retrospectively. Inclusion criteri required receiving one or more doses of olnzpine for the rescue or prophylxis of CINV nd documenttion of the outcome. Results: A totl of 154 ptients nd 193 tretment cycles were included in the brekthrough setting, while totl of 16 ptients nd 20 tretment cycles were included in the prophylxis setting. In the brekthrough setting, 88% of cses experienced improved nuse, while 21% of cses reported improved vomiting. In the prophylctic setting, 100% of cses experienced improved nuse, while 65% chieved improved vomiting. A totl of 43% of cses in the brekthrough setting nd 65% of cses in the prophylctic setting experienced sedtion. Conclusions: Olnzpine is effective in improving CINV in both the prophylctic nd brekthrough settings. The sfety, efficcy, nd pproprite dosge of olnzpine for the rescue of brekthrough CINV should be prospectively evluted in rndomized controlled tril (RCT). Keywords: Olnzpine; chemotherpy-induced nuse nd vomiting (CINV); brekthrough emesis; prophylxis; efficcy Submitted Dec 31, Accepted for publiction Mr 18, doi: /pm View this rticle t: Introduction Chemotherpy-induced nuse nd vomiting (CINV) is well-documented dverse effect for ptients undergoing chemotherpy tretment (1-5). Left untreted, CINV my result in serious complictions, thus potentilly compromising outcome if dose reduction or discontinution of therpy is required (6). At present, current ntiemetic guidelines recommend tht three-drug combintion of 5-HT 3 ntgonist, dexmethsone, nd neurokinin 1 (NK-1) inhibitors be used in the prophylxis of cute CINV in the highly emetogenic chemotherpy (HEC) settings, while two-drug combintion of plonosetron nd dexmethsone is recommended in the modertely emetogenic chemotherpy settings (MEC) (7,8). For
2 Annls of Pllitive Medicine, Vol 5, No 3 July 2016 delyed CINV, combintion of dexmethsone nd prepitnt is recommended in the HEC settings, while dexmethsone or prepitnt cn be used in MEC settings (7,8). However, despite prophylctic tretment, CINV my nevertheless rise. Filure to control CINV with the id of prophylctic ntiemetics is defined s brekthrough CINV (8), nd t present, mny medictions re recommended by clinicl guidelines but no specific gent for this type of CINV is preferred (8). Olnzpine is n ntipsychotic mediction with cliniclly observed ntiemetic effects (9). The Food nd Drug Administrtion (FDA) pproved drug blocks multiple neurotrnsmitters: dopmine t D1, D2, D3 nd D4 brin receptors, serotonin t 5-HT 2, 5-HT 2c, 5-HT 3, nd 5-HT 6 receptors, ctecholmines t lph-1 drenergic receptors, cetylcholine t muscrinic receptors, nd histmine t H1 receptors (10). Since 2000, when cse report first documented the efficcy of olnzpine in relieving the chronic nuse of leukemi ptient (11), severl phse I nd II studies (12-18), other rndomized controlled trils (RCTs) (19-23), nd recent systemtic reviews nd met-nlyses (24,25), hve been published which document the effective use of olnzpine s prophylctic ntiemetic in controlling CINV. However, only two studies hve documented the use of olnzpine for the rescue of brekthrough CINV (26,27). With the reltively few number of studies in the literture documenting olnzpine in the brekthrough setting, the primry objective of this study ws to determine the efficcy nd sfety of olnzpine when given s rescue mediction to ptients who experience brekthrough CINV. The secondry objective ws to determine the efficcy nd sfety of olnzpine s prophylxis tretment of CINV. Methods Study design nd ptient selection Following pprovl from the Toronto Acdemic Helth Sciences Network (TAHSN) Reserch Ethics Bord, electronic medicl records of dult ptients ged >17 yers receiving prescription for olnzpine from the Odette Cncer Centre Phrmcy t Sunnybrook Hospitl between Jnury 2013 nd June 2015 were reviewed retrospectively. Inclusion criteri required receiving one or more doses of olnzpine for the rescue or prophylxis of CINV nd documenttion of the outcome. In the prophylctic setting, olnzpine ws dministered for the first three dys fter chemotherpy, strting on the dy of chemotherpy, twice 173 dy. In the brekthrough setting, ech ptient must hve received some form of stndrd prophylctic ntiemetic before the dministrtion of first-line rescue ntiemetic. First-line rescue ntiemetic is defined s the subsequent ntiemetic mediction given fter clinicl filure of prophylctic ntiemetics. Olnzpine ws dministered s the first-line rescue ntiemetic for the mjority of ptients. Other ptients my hve used prochlorperzine s firstline rescue mediction, but switched to olnzpine becuse of clinicl filure or the mediction induced side effects severe enough to wrrnt discontinution by the ptient. Olnzpine dministrtion for brekthrough CINV must hve been given fter clinicl filure of prophylctic ntiemetics nd/or filure of non-olnzpine contining first-line rescue. In the rescue setting, ech mediction ws lwys dministered seprtely nd sequentilly. Ptients were excluded if olnzpine ws used before chemotherpy. In both the rescue nd prophylctic settings, the primry outcome mesure ws the percentge of ptients who took olnzpine nd found it to improve nuse or vomiting. In both the nuse nd vomiting endpoints, filure ws defined s the ptient indicting CINV to be sme or worse upon olnzpine use. Secondry outcome mesures included the percentge of ptients who took olnzpine nd developed side effects. Ptients were strtified by chemotherpy emetogenicity level nd type, number of prophylctic ntiemetics received, dosge of olnzpine used, tretment intent, s well s by risk fctors such s ge, gender, nd lcohol consumption. Chemotherpy emetogenicity levels were seprted into high, medium nd low potentils, prophylctic nti-emetics divided into groups of single, double, or triple gents, dosge of olnzpine ws exmined in either 2.5 or 5 mg, nd tretment intent into djuvnt, neodjuvnt, pllitive, or curtive. Risk fctors were seprted into ge younger thn 55 versus ge 55 yers or older nd lcohol use less thn 5 drinks/week versus use of 5 drinks/week or more. Assessment procedures At the Odette Cncer Centre, ptients re followed up with phone cll by phrmcist or phrmcy reserch ssistnt 72 hours fter every cycle of chemotherpy. Any outcomes of CINV for the initil cycle fter this 72-hour period would be mde in the next tretment cycle in the hospitl or within the 72 hour period follow-up in the next cycle. An ssessment of CINV ws documented in the ptient s electronic medicl records. In both the prophylctic nd
3 174 Chiu et l. Olnzpine for prophylxis nd rescue of CINV: retrospective study Tble 1 Ptient demogrphics nd bseline risk fctors Chrcteristic Age (yers) Medin 51 Rnge Gender brekthrough setting, ptients were sked whether they experienced improved, worse, or sme CINV fter tking olnzpine. Sttisticl methods Totl (n=170, 100%) No. % Femle Mle Primry cncer site Brest Gstrointestinl H/N Gynecology Hemtology Lung Genitourinry Other Bseline risk fctors Age (yers) > Alcohol use >5 drinks/week No Yes Any cffeine use No Yes Any tobcco use No Yes Descriptive nlysis ws conducted using medin nd rnges for continuous vribles nd proportions for ctegoricl vribles. To compre olnzpine outcomes on clinicl fctors, Wilcoxon rnk-sum (for two ctegories of olnzpine outcomes) or Kruskl-Wllis (for >2 ctegories of olnzpine outcomes) nonprmetric test ws used for continuous vribles nd Chi-squred test or Fisher exct test ws used s pproprite for ctegoricl vribles. Twosided P vlue <0.05 ws considered sttisticlly significnt. All nlyses were performed by Sttisticl Anlysis Softwre (SAS version 9.4 for Windows). Results Ptient chrcteristics A totl of 170 ptients nd 213 tretment cycles were included: 142 women nd 28 men with men ge of 50.9 yers (rnge, 19 77) (Tble 1). The most common primry cncer site ws brest cncer (n=97, 57%) (Tble 1). Other demogrphic informtion, including bseline risk fctors such s lcohol nd cffeine consumption, cn be found in Tble 1. Efficcy nd sfety prmeters in the brekthrough setting A totl of 154 ptients nd 193 tretment cycles were included in the brekthrough setting (Tble 2). Tble 3 documents the proportion of ptients with different olnzpine outcomes for nuse nd vomiting in the brekthrough setting. Subgroup nlysis reveled tht the effectiveness of olnzpine for brekthrough CINV ws not dependent on the cycle it strts on (P=0.3), nor ws it dependent on the emetogenic potentil (P=0.1), the tretment intent (P=0.2), or the type (P=0.3) of the chemotherpy regimen. In ddition, there is no significnt reltionship between hving single, double, or triple prophylctic ntiemetic regimen nd subsequent olnzpine outcomes (P=0.4). In ddition, there ws no significnt difference on side effects or outcomes between the use of 2.5 or 5 mg dose of olnzpine. No significnt reltionship between bseline demogrphics nd different olnzpine outcomes were found either. Efficcy nd sfety prmeters in the prophylctic setting A totl of 16 ptients nd 20 tretment cycles were included in the prophylxis setting (Tble 4). In ll 16 ptients nd 20 cses, olnzpine use ws indicted by ptients to hve improved nuse in the prophylctic setting, while
4 Annls of Pllitive Medicine, Vol 5, No 3 July Tble 2 Tretment cycles nd ntiemetics in the brekthrough setting Chrcteristic Number of tretment cycles with olnzpine use Medin 1 Rnge 1 12 Emetogenic potentil (n =193, 100%) No. % High High/low Low Medium Olnzpine dose 2.5 mg mg Tretment intent Adjuvnt Neodjuvnt Pllitive Curtive Prophylctic nti-emetics Single (dexmethsome or 5-HT 3 ntgonist) Double (5-HT 3 ntgonist nd prepitnt) Triple (5-HT 3 ntgonist, dexmethsome, prepitnt) Type of rescue medictions Olnzpine Prochlorperzine, olnzpine Olnzpine, prochlorperzine Olnzpine, domperidone Prochlorperzine, domperidone, olnzpine Prochlorperzine, olnzpine, metocloprmide 6 3.1, tretment cycles. 7 cses (35%) chieved improved vomiting (Tble 3). A totl of 65% of the cses indicted the feeling of sedtion fter olnzpine use, while 35% of the cses indicted experiencing constiption (Tble 5). As in the brekthrough setting, subgroup nlysis reveled Tble 3 Proportion of ptients with different outcomes upon use of olnzpine for brekthrough CINV or the prevention of CINV Olnzpine outcomes tht the effectiveness of olnzpine for the prevention of CINV ws not dependent on the cycle it strts on (P=0.98), the emetogenic potentil (P=0.6), the tretment intent (P=0.9), or the type (P=0.4) of the chemotherpy regimen. Moreover, there ws no significnt reltionship between hving single, double, or triple prophylctic ntiemetic regimen nd subsequent olnzpine outcomes (P=0.5). Although there ws no significnt difference between the use of 2.5 or 5 mg dose of olnzpine with respect to the ntiemetic outcome or the incidence of constiption, there ws significnt difference between the two doses with regrds to the incidence of sedtion. The use of 5 mg olnzpine dose ws ssocited with significntly higher proportions of sedtion compred to 2.5 mg dose (P=0.03). Discussion Rescue setting (n=193, 100%) Prophylxis setting (n=20, 100%) No. % No. % b Improved nuse Improved vomiting Filure nuse c Filure vomiting d , totl number of chemotherpy cycles [193] is used s the denomintor for clculting the proportions in this setting; b, totl number of chemotherpy cycles [20] is used s the denomintor for clculting the proportions in this setting; c, filure nuse is defined s worse or sme nuse level despite the use of olnzpine; d, filure vomiting is defined s worse or mount of vomiting despite the use of olnzpine. CINV, chemotherpy-induced nuse nd vomiting. The efficcy of olnzpine in the prophylxis of CINV hs been documented (12-23). However, literture on the use of olnzpine s rescue mediction for brekthrough CINV hs been scrce, with only two studies investigting the use of olnzpine for this purpose (26,27). As such, we focus on the two rticles by Chnthwong et l. (26) nd Nvri et l. (27) s frmework for our discussion. The current study retrospectively detils the efficcy nd sfety of olnzpine for the tretment of brekthrough CINV. It is the lrgest study of this nture to dte, with totl of 154 ptients nd 193 tretment cycles in the
5 176 Chiu et l. Olnzpine for prophylxis nd rescue of CINV: retrospective study Tble 4 Tretment cycles nd ntiemetics in the prophylctic setting Chrcteristic Number of tretment cycles with olnzpine use Medin 1 Rnge 1 10 Emetogenic potentil (n =20, 100%) No. % High Low Medium Olnzpine dose 2.5 mg mg Tretment intent Adjuvnt Neodjuvnt Pllitive Curtive Prophylctic nti-emetics Double (5-HT 3 ntgonist nd prepitnt) Triple (5-HT 3 ntgonist, dexmethsome, prepitnt) Olnzpine , tretment cycles. brekthrough setting. With pproximtely 88% of cses indicting tht olnzpine improved brekthrough nuse, the proportion in this study is, s expected, higher thn the 68% of ptients in the Nvri study tht indicted no nuse (27), nd the complete response in nuse rte of 50% reported by Chnthwong et l. (26). The proportion of improved vomiting (22%) in our study is considerbly lower thn the no emesis (70%) nd complete response in emesis (60.9%) rtes reported by Nvri et l. nd Chnthwong et l., respectively. In the Chnthwong study, complete response in nuse ws s no emetic episodes, no rescue therpy nd no nuse, while the complete response in emesis ws defined s no emetic episodes nd no rescue therpy. It should be noted tht the doses used by Nvri et l. nd Chnthwong et l. were 10 mg dily nd 5 mg twice dy, respectively. Given tht the methodology used in this study is different from the ones used by Chnthwong et l. nd Nvri et l., the results re not comprble. Specificlly, the study by Chnthwong et l. is phse II prospective open lbel clinicl tril tht mesured the rtes of complete response for brekthrough emesis, retching nd nuse using the Index of Nuse, Vomiting nd Retching: INVR tool. The study by Nvri et l. is rndomized phse III tril tht mesured rtes of complete response using visul nlog scle from 0 to 10, with 0 indicting no nuse nd 10 indicting mximl level of nuse. On the other hnd, the retrospective nture of this study nd the limited informtion vilble from the electronic medicl records limited this study s bility to report on the more commonly used endpoints in ntiemetic Tble 5 Proportion of ptients who took olnzpine nd developed certin side-effects Side effect Rescue setting (n=193, 100%) Prophylxis setting (n=20, 100%) No. % No. % b Sedtion Sedtion with continution of olnzpine Sedtion with discontinution of olnzpine Constiption Mild, constiption, no mediction prescribed Severe constiption with prescribed medictions , totl number of chemotherpy cycles [193] is used s the denomintor for clculting the proportions in this setting; b, totl number of chemotherpy cycles [20] is used s the denomintor for clculting the proportions in this setting.
6 Annls of Pllitive Medicine, Vol 5, No 3 July 2016 clinicl trils such s no emesis nd no nuse. Moreover, the proportions of improvement for nuse nd vomiting my be under-estimted. As documenttion is predicted on phone-cll follow-up, improvement of CINV my not lwys be communicted by ptients. This study is the first to report the proportion of ptients tht experienced side effects in the brekthrough setting, with 42% of cses experiencing sedtion nd 32% experiencing constiption. With 65% of ptients experiencing sedtion in the prophylctic setting, this study reports the incidence of sedtion to be lower thn the 73% indicted by study by Tn et l. (19). It should be noted tht in our study, olnzpine ws dministered in smller 2.5 or 5 mg doses thn the 10 mg dose used by Tn et l. Our findings tht 2.5 mg dose of olnzpine in the prophylctic setting is ssocited with similr CINV outcomes, but smller incidence of sedtion thn 5 mg dose further support the recommendtion of dosge reduction. While it is well known tht the emetogenicity of chemotherpy dministered, gender, ge, s well s history of low prior lcohol intke, cn ffect ptients risk fctors for CINV (28), it is reltively unknown whether the before mentioned bseline risk fctors cn ffect the efficcy of olnzpine use. Our study found no significnt differences between ptients with bseline risk fctors nd those without, in both the prophylxis nd brekthrough settings. Our study lso found tht the effectiveness of olnzpine in both the prophylxis nd brekthrough settings is not dependent on the cycle it strted on. This study is limited by its retrospective design. Specificlly, informtion on the intensity of brekthrough nuse or the number of brekthrough vomiting episodes before nd fter the use of olnzpine ws not recorded, nd thus, more stndrd definitions of filure in the tretment of brekthrough CINV could not be used. In ddition, ptients received different combintions of prophylctic nti-emetics tht my hve confounded the efficcy of olnzpine for brekthrough CINV. However, mesures hve been tken to minimize its limittions. For exmple, our nlysis showed tht there ws no significnt difference between receiving single gent prophylctic nti-emetic (dexmethsone or 5-HT 3 ntgonist), double gent ntiemetic ( 5-HT 3 ntgonist coupled with NK-1 inhibitor), or triple gent nti-emetic ( 5-HT 3 ntgonist, dexmethsone, nd NK-1 inhibitor) with respect to the efficcy of olnzpine s rescue mediction for brekthrough CINV. In conclusion, this study found olnzpine to be effective in improving CINV in both the prophylctic nd 177 brekthrough settings. The incidence of sedtion in both settings ws found to be lower thn the only other reported incidence of sedtion of 73%, though it should be noted tht our study used lower doses. Given the similr benefit fforded by 2.5 nd 5 mg dose, we recommend the use of lower doses of olnzpine in both the prophylctic nd brekthrough settings. The sfety, efficcy, nd pproprite dosge of olnzpine for the rescue of brekthrough CINV should be prospectively evluted in RCT. Acknowledgements We thnk the generous support of Brtty Fmily Fund, Michel nd Kryn Goldstein Cncer Reserch Fund, Joey nd Mry Furfri Cncer Reserch Fund, Pulenzs Cncer Reserch Fund, Joseph nd Silvn Melr Cncer Reserch Fund, nd Ofeli Cncer Reserch Fund. Footnote Conflicts of Interest: The uthors hve no conflicts of interest to declre. Ethicl Sttement: The study ws pproved by the Toronto Acdemic Helth Sciences Network (TAHSN) Reserch Ethics Bord. References 1. Cotes A, Abrhm S, Kye SB, et l. On the receiving end--ptient perception of the side-effects of cncer chemotherpy. Eur J Cncer Clin Oncol 1983;19: Lszlo J. Nuse nd vomiting s mjor complictions of cncer chemotherpy. Drugs 1983;25 Suppl 1: Levine AM, Richrdson JL, Mrks G, et l. Complince with orl drug therpy in ptients with hemtologic mlignncy. J Clin Oncol 1987;5: Lindley CM, Bernrd S, Fields SM. Incidence nd durtion of chemotherpy-induced nuse nd vomiting in the outptient oncology popultion. J Clin Oncol 1989;7: Richrdson JL, Mrks G, Levine A. The influence of symptoms of disese nd side effects of tretment on complince with cncer therpy. J Clin Oncol 1988;6: Osob D, Zee B, Wrr D, et l. Effect of postchemotherpy nuse nd vomiting on helth-relted qulity of life. The Qulity of Life nd Symptom Control Committees of the Ntionl Cncer Institute of Cnd Clinicl Trils Group.
7 178 Chiu et l. Olnzpine for prophylxis nd rescue of CINV: retrospective study Support Cre Cncer 1997;5: Bsch E, Prestrud AA, Hesketh PJ, et l. Antiemetics: Americn Society of Clinicl Oncology clinicl prctice guideline updte. J Clin Oncol 2011;29: Roil F, Herrstedt J, Apro M, et l. Guideline updte for MASCC nd ESMO in the prevention of chemotherpynd rdiotherpy-induced nuse nd vomiting: results of the Perugi consensus conference. Ann Oncol 2010;21 Suppl 5:v Kst RE, Foley KF. Cncer chemotherpy nd cchexi: mirtzpine nd olnzpine re 5-HT3 ntgonists with good ntinuse effects. Eur J Cncer Cre (Engl) 2007;16: Srivstv M, Brito-Delln N, Dvis MP, et l. Olnzpine s n ntiemetic in refrctory nuse nd vomiting in dvnced cncer. J Pin Symptom Mnge 2003;25: Pirl WF, Roth AJ. Remission of chemotherpy-induced emesis with concurrent olnzpine tretment: cse report. Psychooncology 2000;9: Nvri RM, Einhorn LH, Pssik SD, et l. A phse II tril of olnzpine for the prevention of chemotherpy-induced nuse nd vomiting: Hoosier Oncology Group study. Support Cre Cncer 2005;13: Pssik SD, Nvri RM, Jung SH, et l. A phse I tril of olnzpine (Zyprex) for the prevention of delyed emesis in cncer ptients: Hoosier Oncology Group study. Cncer Invest 2004;22: Pssik SD, Kirsh KL, Theobld DE, et l. A retrospective chrt review of the use of olnzpine for the prevention of delyed emesis in cncer ptients. J Pin Symptom Mnge 2003;25: Pssik SD, Lundberg J, Kirsh KL, et l. A pilot explortion of the ntiemetic ctivity of olnzpine for the relief of nuse in ptients with dvnced cncer nd pin. J Pin Symptom Mnge 2002;23: Nvri RM, Einhorn LH, Loehrer PJ Sr, et l. A phse II tril of olnzpine, dexmethsone, nd plonosetron for the prevention of chemotherpy-induced nuse nd vomiting: Hoosier oncology group study. Support Cre Cncer 2007;15: Abe M, Ksmtsu Y, Kdo N, et l. Efficcy of Olnzpine Combined Therpy for Ptients Receiving Highly Emetogenic Chemotherpy Resistnt to Stndrd Antiemetic Therpy. Biomed Res Int 2015;2015: Abe M, Hirshim Y, Ksmtsu Y, et l. Efficcy nd sfety of olnzpine combined with prepitnt, plonosetron, nd dexmethsone for preventing nuse nd vomiting induced by cispltin-bsed chemotherpy in gynecologicl cncer: KCOG-G1301 phse II tril. Support Cre Cncer 2016;24: Tn L, Liu J, Liu X, et l. Clinicl reserch of Olnzpine for prevention of chemotherpy-induced nuse nd vomiting. J Exp Clin Cncer Res 2009;28: Mizukmi N, Ymuchi M, Koike K, et l. Olnzpine for the prevention of chemotherpy-induced nuse nd vomiting in ptients receiving highly or modertely emetogenic chemotherpy: rndomized, double-blind, plcebo-controlled study. J Pin Symptom Mnge 2014;47: Wng X, Wng L, Wng H, et l. Effectiveness of Olnzpine Combined with Ondnsetron in Prevention of Chemotherpy-Induced Nuse nd Vomiting of Nonsmll Cell Lung Cncer. Cell Biochem Biophys [Epub hed of print]. 22. Mo WK, Peng L. Clinicl observtion of Olnzpine combined with Grnisetrom nd Hexdecdrol prevent nuse vomit induced by chemordiontherpy. Chinese Journl of Medicine Guide 2011;13: Lu YL, Liu W, Du YJ, et l. Antiemetic effect of low dose olnzpine in solid tumor chemotherpy. Clin J Cncer Prev Tret 2013;20: Chow R, Chiu L, Nvri R, et l. Efficcy nd sfety of olnzpine for the prophylxis of chemotherpy-induced nuse nd vomiting (CINV) s reported in phse I nd II studies: systemtic review. Support Cre Cncer 2016;24: Chiu L, Chow R, Popovic M, et l. Efficcy of olnzpine for the prophylxis nd rescue of chemotherpy-induced nuse nd vomiting (CINV): systemtic review nd met-nlysis. Support Cre Cncer 2016;24: Chnthwong S, Subongkot S, Sookprsert A. Effectiveness of olnzpine for the tretment of brekthrough chemotherpy induced nuse nd vomiting. J Med Assoc Thi 2014;97: Nvri RM, Ngy CK, Gry SE. The use of olnzpine versus metocloprmide for the tretment of brekthrough chemotherpy-induced nuse nd vomiting in ptients receiving highly emetogenic chemotherpy. Support Cre Cncer 2013;21: Nvri RM. Mngement of chemotherpy-induced nuse nd vomiting : focus on newer gents nd new uses for older gents. Drugs 2013;73: Cite this rticle s: Chiu L, Chiu N, Chow R, Zhng L, Psetk M, Stinson J, Lechner B, Pulenzs N, Verm S, Chow E, DeAngelis C. Olnzpine for the prophylxis nd rescue of chemotherpy-induced nuse nd vomiting (CINV): retrospective study.. doi: /pm
Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationTR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:
(2000) 26, 203 210 2000 Mcmilln Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nture.com/bmt Double-blind, rndomized, prllel-group study on the efficcy nd sfety of orl grnisetron nd orl ondnsetron
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationPatients with cancer are at an increased
Risk of Cncer-Associted Thrombosis nd Bleeding in Veterns With Mlignncy Who Are Receiving Direct Orl Anticogulnts Mtthew Stnkowicz, PhrmD; Megn Bnszynski, PhrmD, BCOP; nd Russell Crwford, BPhrm, BCOP The
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationAge related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer
MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,
More informationAssessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II
Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationBody mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health
Originl Article - Sexul Dysfunction/Infertility pissn 2005-6737 eissn 2005-6745 Body mss index, wist-to-hip rtio, nd metbolic syndrome s predictors of middle-ged men's helth Jung Hyun Prk *, In-Chng Cho
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationTrends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
ORIGINAL ARTICLE Trends in ntihypertensive nd lipidlowering therpy in subjects with type II dibetes: clinicl effectiveness or clinicl discretion? MC Gulliford, J Chrlton nd R Ltinovic Deprtment of Public
More informationMetabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction
Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson
More informationResults. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)
Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationInhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD
CHEST Originl Reserch Inhled Corticosteroid Is Associted With n Incresed Risk of TB in Ptients With COPD Jung-Hyun Kim, MD ; Ji-Soo Prk, MD ; Kyung-Ho Kim, MD ; Hye-Cheol Jeong, MD ; Eun-Kyung Kim, MD
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationA cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis
Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu
More informationEffect on Glycemic, Blood Pressure, and Lipid Control according to Education Types
Originl Article http://dx.doi.org/10.4093/dmj.2011.35.6.580 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L Effect on Glycemic, Blood Pressure, nd Lipid Control ccording
More informationDrug Utilization Review of Potassium Chloride Injection Formulations Available in a Private Hospital in Kuching, Sarawak, Malaysia
Originl Article Drug Utiliztion Review of Potssium Chloride Injection Formultions Avilble in Privte Hospitl in Kuching, Srwk, Mlysi Mohmmd Hirmn Meliss 1, Srriff Azmi 2 Submitted: 24 Oct 2012 Accepted:
More informationDiabetes affects 29 million Americans, imposing a substantial
CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.
More informationHealth Coaching: A Preliminary Report on the Effects in Traumatic Brain Injury/Polytrauma Patients
ORIGINAL RESEARCH Helth Coching: A Preliminry Report on the Effects in Trumtic Brin Injury/Polytrum Ptients Esmerld Mdrigl, MSW; Mx Gry, BA; Molly A. Timmermn, DO; Ttin Orozco, PhD; Dine Cowper Ripley,
More informationThe potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens
The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic
More informationChilblains (pernio, perniosis) are cold-induced, painful or itching
Nifedipine vs Plcebo for Tretment of Chronic Chilblins: A Rndomized Controlled Tril Ibo H. Souwer, MD 1 Jcobus H. J. Bor, BSc (Mth) 2 Pul Smits, MD, PhD 3 Antoine L. M. Lgro-Jnssen, MD, PhD 1 1 Deprtment
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. doi: /ajg.2012.
A 12-Week, Rndomized, Controlled Tril with 4-Week Rndomized Withdrwl Period to Evlute the Efficcy nd Sfety of Linclotide in Irritble Bowel Syndrome with Constiption The Hrvrd community hs mde this rticle
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationUtilization of dental services in Southern China. Lo, ECM; Lin, HC; Wang, ZJ; Wong, MCM; Schwarz, E
Title Utiliztion of dentl services in Southern Chin Author(s) Lo, ECM; Lin, HC; Wng, ZJ; Wong, MCM; Schwrz, E Cittion Journl Of Dentl Reserch, 2001, v. 80 n. 5, p. 1471-1474 Issued Dte 2001 URL http://hdl.hndle.net/10722/53200
More informationBreast-Conserving Surgery Under Local Anesthesia in Elderly Patients with Severe Cardiorespiratory Comorbidities: A Hospital-Based Case-Control Study
Originl Article Brest Cre 2017;12:29 33 DOI: 10.1159/000455003 Published online: Februry 8, 2017 Brest-Conserving Surgery Under Locl in Elderly Ptients with Severe Crdiorespirtory Comorbidities: A Hospitl-Bsed
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationImpact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors
Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms
More informationEVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1
Swine Dy 2001 Contents EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 C. W. Hstd, S. S. Dritz 2, J. L. Nelssen, M. D. Tokch, nd R. D. Goodbnd Summry Two trils were
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationkey words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous
reserch report Effect of Route of Bortezomib Administrtion on Tretment Outcomes in Previously Untreted Ptients with Multiple Myelom: A Retrospective Anlysis from US Community Oncology Prctices Robert M
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationOriginal Article. Breast Care 2016;11: DOI: /
Originl Article Brest Cre 2016;11:323 327 DOI: 10.1159/000452079 Published online: October 24, 2016 Neodjuvnt Chemotherpy with Docetxel, Crbopltin nd Weekly Trstuzumb Is Active in HER2-Positive Erly Brest
More informationA Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
ORIGINAL CONTRIBUTIONS 3 see relted editoril on pge x A Rndomized Phse III Clinicl Tril of Plecntide, Urogunylin Anlog, in Ptients With Chronic Idiopthic Constiption Philip B. Miner Jr, MD, Willim D. Koltun,
More informationComparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy
Comprtive Sfety of Filgrstim versus Srgrmostim in Ptients Receiving Myelosuppressive Chemotherpy Gry Milkovich, B.S., Ronld J. Moleski, Phrm.D., John F. Reitn, Phrm.D., Dvid M. Dunning, M.D., Gene A. Gibson,
More informationGoal: Evaluate plant health effects while suppressing dollar spot and brown patch
Newer Fungicide Products Alone nd In Rottion on Chicgo Golf Green Reserchers: Chicgo District Golf Assoc. Derek Settle, Tim Sibicky, nd Nick DeVries Gol: Evlute plnt helth effects while suppressing dollr
More informationIncreased Relative Mortality in Women With Severe Oxygen-Dependent COPD
CHEST Originl Reserch Incresed Reltive Mortlity in Women With Severe Oxygen-Dependent COPD Mgnus Ekström, MD ; Krl A. Frnklin, MD, PhD ; nd Kerstin E. Ström, MD, PhD COPD Bckground: Although the incidence
More informationAntiviral Therapy 2015; 20: (doi: /IMP2874)
Antivirl Therpy 25; 2:79 79 (doi:.385/imp2874) Originl rticle Single dose permivir for the tretment of cute sesonl influenz: integrted nlysis of efficcy nd sfety from two plcebo-controlled trils Richrd
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationChronic obstructive pulmonary disease (COPD) is the third
METHODS Clims-Bsed Risk Model for First Severe COPD Excerbtion Richrd H. Stnford, PhrmD, MS; Arpit Ng, PhD, MBA, MS; Dougls W. Mpel, MD; Todd A. Lee, PhD; Richrd Rosiello, MD; Michel Schtz, MD; Frncis
More informationThe STAR*D trial is the largest and most consequential antidepressant study
CnJPsychitry 2015;60(1):9 13 Perspective The STAR*D Tril: It Is Time to Reexmine the Clinicl Beliefs Tht Guide the Tretment of Mjor Depression H Edmund Pigott, PhD 1 1 Chief Clinicl Officer, Positive Brin
More informationThe Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes
Originl Article doi: 10.4093/kdj.2010.34.3.166 pissn 1976-9180 eissn 2093-2650 The Effects of Smll Sized Rice Bowl on Crbohydrte Intke nd Dietry Ptterns in Women with Type 2 Dibetes Hee-Jung Ahn 1, *,
More informationRelationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients
J Renl Inj Prev. 2017; 6(2): 88-92. http://journlrip.com Journl of Renl Injury Prevention DOI: 10.15171/jrip.2017.17 Reltionship between serum irisin, glycemic indices, nd renl function in type 2 dibetic
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationOriginal Article. Diabetes Metab J 2011;35:26-33 doi: /dmj pissn eissn
Originl Article Dibetes Metb J 211;35:26-33 doi: 1.493/dmj.211.35.1.26 pissn 2233-679 eissn 2233-687 D I A B E T E S & M E T A B O L I S M J O U R N A L Comprison of the Efficcy of Glimepiride, Metformin,
More informationThe Acute Time Course of Concurrent Activation Potentiation
Mrquette University e-publictions@mrquette Exercise Science Fculty Reserch nd Publictions Exercise Science, Deprtment of 1-1-2010 The Acute Time Course of Concurrent Activtion Potentition Luke Grceu Mrquette
More informationInput from external experts and manufacturer on the 2 nd draft project plan Stool DNA testing for early detection of colorectal cancer
Input externl experts nd mnufcturer on the 2 nd drft project pln Stool DNA testing for erly detection of colorectl cncer (Project ID:OTJA10) All s nd uthor s replies on the 2nd drft project pln Stool DNA
More informationRelationship Between Hospital Performance on a Patient Satisfaction Survey and Surgical Quality
Reserch Originl Investigtion Reltionship Between Hospitl Performnce on Ptient Stisfction Survey nd Surgicl Qulity Greg D. Scks, MD, MPH; Elise H. Lwson, MD, MSHS; Aron J. Dwes, MD; Mrci M. Russell, MD;
More informationDiabetes is a chronic and highly prevalent condition that
Mediction Adherence nd Improved Outcomes Among Ptients With Type 2 Dibetes Srh E. Curtis, MPH; Kristin S. Boye, PhD; Mureen J. Lge, PhD; nd Luis-Emilio Grci-Perez, MD, PhD Dibetes is chronic nd highly
More informationThe incidence of melanoma, the most serious
Efectiveness nd sfety of ipilimumb therpy in dvnced melnom: evidence from clinicl prctice sites in the US Kim A Mrgolin, MD, Ahmd Trhini, MD, PhD, b Sumti Ro, PhD, c Monic Ktyl, JD, MPH, d I-Fen Chng,
More informationCheckMate-142 Study Design
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Thierry André, 1 Sr
More informationBudesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
Journl of Crohn's nd Colitis, 2017, 785 791 doi:10.1093/ecco-jcc/jjx032 Advnce Access publiction Mrch 4, 2017 Originl Article Originl Article Budesonide Multimtrix Is Efficcious for Meslmine-refrctory,
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BASAGLAR sfely nd effectively. See full prescribing informtion for BASAGLAR BASAGLAR (insulin glrgine
More informationClinicalTrials.gov Identifier: NCT
Efficcy of Drtumumb, Lenlidomide, nd Dexmethsone Versus Lenlidomide nd Dexmethsone in Relpsed or Refrctory Multiple Myelom Ptients With to 3 Prior Lines of Therpy: Updted Anlysis of POLLUX Sd Z. Usmni,
More informationRisks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
Clinicl Prctice: Mini-Review Received: My 20, 2016 Accepted fter revision: December 14, 2016 Published online: Jnury 27, 2017 Risks for All-Cuse Mortlity: Strtified by Age, Estimted Glomerulr Filtrtion
More informationClinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population
Originl Article Clinicl sttistics nlysis on the chrcteristics of pneumoconiosis of Chinese miner popultion Mei-Fng Wng 1 *, Run-Ze Li 2 *, Ying Li 2, Xue-Qin Cheng 1, Jun Yng 1, Wen Chen 3, Xing-Xing Fn
More informationRecall Bias in Childhood Atopic Diseases Among Adults in The Odense Adolescence Cohort Study
Syddnsk Universitet Recll Bis in Childhood Atopic Diseses Among Adults in The Odense Adolescence Cohort Study Mørtz, Chrlotte G; Andersen, Klus Ejner; Bindslev-Jensen, Crsten Published in: Act Dermto-Venereologic
More informationTHE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS
THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS John F. Ptience nd Doug Gillis SUMMARY
More informationURINARY incontinence is an important and common
Urinry incontinence in older people in the community: neglected problem? Helen Stoddrt, Jenny Donovn, Elise Whitley, Deborh Shrp nd In Hrvey SUMMARY Bckground: The prevlence nd impct of urinry incontinence
More informationSafety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Sfety of Ocrelizumb in Multiple Sclerosis: Updted Anlysis in Ptients With Relpsing nd Primry Progressive Multiple Sclerosis SL Huser, L Kppos, X Montlbn, H Koendgen, C Chognot, C Li, C Mrcillt, A Prdhn,
More informationResearch Article Patterns of Cancer Genetic Testing: A Randomized Survey of Oregon Clinicians
Hindwi Publishing Corportion Journl of Cncer Epidemiology Volume 2012, Article ID 294730, 11 pges doi:10.1155/2012/294730 Reserch Article Ptterns of Cncer Genetic Testing: A Rndomized Survey of Oregon
More information10-15 mg/day 15 mg/day 30 mg/day. 2-5 mg/day 5-10 mg/day 15 mg/day. 2 mg/day 5-10 mg/day 15 mg/day. 30 mg/day injected IM
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ABILIFY sfely nd effectively. See full prescribing informtion for ABILIFY. Tblets ABILIFY DISCMELT
More informationPatient-Controlled Transdermal Fentanyl Versus Intravenous Morphine Pump After Spine Surgery
Ptient-Controlled Trnsderml Fentnyl Versus Intrvenous Morphine Pump After Spine Surgery Emily M. Lindley, PhD; Kenneth Millign, BS; Ryn Frmer, MD; Evlin L. Burger, MD; Viks V. Ptel, MD bstrct Ptient-controlled
More informationManagement and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence
Clinicin Summry Mentl Helth Eting Disorders Mngement nd Outcomes of Binge-Eting Disorder in Adults: Current Stte of the Evidence Focus of This Summry This is summry of systemtic review evluting the evidence
More informationMultiple sclerosis (MS) affects approximately. Triaging Patients with Multiple Sclerosis in the Emergency Department. Room for Improvement
Systemtic Review of Tools for Anxiety in MS MS CARE DELIVERY: CHALLENGES AND INVATIONS Triging Ptients with Multiple Sclerosis in the Emergency Deprtment Room for Improvement Heshm Abboud, MD, PhD; Krin
More informationEFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE
Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.
More informationPotential for Interactions Between Dietary Supplements and Prescription Medications a
CLINICAL RESEARCH STUDY Potentil for Interctions Between Dietry Supplements nd Prescription Medictions Amit Sood, MD, MSc, Rich Sood, MD, b Frncis J. Brinker, ND, Rvneet Mnn, MBBS, c Lur L. Loehrer, Dietlind
More informationUsing proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience
ORIGINAL ARTICLE Using prolifertive mrkers nd Oncotype DX in therpeutic decision-mking for brest cncer: the B.C. experience E. Bxter bsc,* L. Gondr btech pdc, C. Lohrisch md, S. Chi md, K. Gelmon md, M.
More informationSummary of Package Insert 1
Summry of Pckge Insert 1 For Sttes with Non-Published Policies Indictions Non-infected prtil nd full-thickness skin ulcers due to VSU 2 of greter thn 1 month durtion nd which hve not dequtely responded
More informationR Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1
Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity
More informationAnalysis of Risk Factors for the Development of Incisional and Parastomal Hernias in Patients after Colorectal Surgery
Originl Article Journl of the Koren Society of J Koren Soc Coloproctol 2012;28(6):299-303 http://dx.doi.org/10.3393/jksc.2012.28.6.299 pissn 2093-7822 eissn 2093-7830 Anlysis of Risk Fctors for the Development
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationLung cancer is the leading cause of cancer death worldwide, EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Originl Article EGFR Muttion nd Brin Metstsis in Pulmonry Adenocrcinoms Dong-Yeop Shin, MD,* Im Il N, MD,* Cheol Hyeon Kim, MD, PhD, Sunhoo Prk, MD, PhD, HeeJong Bek, MD, PhD, nd Sung Hyun Yng, MD, PhD*
More information